Abstract
Previously, we have identified a tumor cell-specific peptide, HEW, by panning of phage display libraries on the human colorectal cancer cell line WiDr. In this report we demonstrate that this peptide can modify the infection properties of adenovirus vectors. Increased infectivity of replication-deficient adenovirus 5 vectors in WiDr cells was observed upon genetic insertion of the HEW peptide in the HI loop of the fiber knob. Moreover, whereas the coxsackie and adenovirus receptor (CAR)-ablating fiber mutation S408E abolished apparent infection in CAR-positive WiDr cells, the insertion of HEW completely restored infectivity toward these cells in vitro. To assess whether the de- and re-targeted infection profile was maintained in vivo, the fiber-modified adenovirus vectors were injected intratumorally or intravenously in WiDr tumor-bearing Swiss nu/nu mice. No significant differences in efficiency of infection could be observed suggesting alternative viral uptake mechanisms in vivo. Next, we have included the fiber shaft mutation S* in our studies, which was described to confer a de-targeted phenotype in vivo. Reduced gene transfer due to the S* mutation both in vitro and in vivo could be confirmed. Insertion of HEW in the HI knob loop of shaft-mutated fiber, however, did not rescue infectivity in target cells neither in vitro nor in vivo. We demonstrate the efficient ligand-mediated re-targeting of adenoviral vector infection to the human cancer cell line WiDr. The lack of apparent re-targeting in the in vivo situation is described.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Noureddini SC, Curiel DT . Genetic targeting strategies for adenoviruses. Mol Pharm 2005; 2: 341–347.
Legrand V, Leissner P, Winter A, Methali M, Lusky M . Transductional targeting with recombinant adenovirus vectors. Curr Gene Ther 2002; 2: 323–339.
Mizuguchi H, Hayakawa T . Targeted adenovirus vectors. Hum Gen Ther 2004; 15: 1034–1044.
Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G . Heparan sulphate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772–8780.
Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G . The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107–115.
Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, Kolls J et al. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195–1206.
Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798–8807.
Nicklin SA, Wu E, Nemerow GR, Baker AH . The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384–393.
Leissner P, Legrand V, Schlesinger Y, Hadji DA, van Raaij M, Cusack S et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 2001; 8: 49–57.
Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002; 5: 770–779.
Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM . Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999; 286: 1579–1583.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins alpha v beta 3 and alpha v beta5 promote adenovirus internalization, but not virus attachment. Cell 1993; 73: 309–319.
Shayakhmetov DM, Eberly AM, Li Z, Lieber A . Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotypes 5 and 35 fiber knobs. J Virol 2005; 79: 1053–1061.
Smith TAG, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003; 14: 777–787.
Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T . Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alpha v integrin binding ablation. J Virol 2003; 77: 13062–13072.
Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, Richter King C, Kovesdi I et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75: 11284–11291.
Smith TAG, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595–1604.
Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H . Modified adenoviral vectors ablated for coxsackievirus adenovirus receptor, alpha v integrin, and heparin sulphate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 2006; 17: 264–279.
Xia H, Anderson B, Mao Q, Davidson BL . Recombinant human adenovirus: targeting to the human transferring receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74: 11359–11366.
Work LM, Nicklin SA, Brain NJR, Dishart KL, von Seggern DJ, Hallek M et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198–208.
Rasmussen UB, Schreiber V, Schultz H, Mischler F, Schughart K . Tumor cell-targeting by phage – displayed peptides. Cancer Gene Ther 2002; 9: 606–612.
Legrand V, Spehner D, Schlesinger Y, Settelen N, Pavirani A, Mehtali M . Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J Virol 1999; 73: 907–919.
Sambruck J, Fritsch EF, Maniatis T . Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1989.
Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M . Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805–4810.
Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD . Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 1994; 68: 5239–5246.
Lutz P, Rosa-Calatrava M, Kedinger C . The product of the adenoviral intermediate gene pIX is a transcriptional activator. J Virol 1997; 71: 5102–5109.
McDonald D, Stockiwin L, Matzow T, Blair Zajdel ME, Blair GE . Cocksackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther 1999; 6: 1497–1498.
Xia D, Henry L, Gerard R, Deisenhofer J . Crystal structure of the receptor-binding domain of adenovirus serotype 5 fiber protein at 1.7 A resolution. Structure 1994; 2: 1259–1270.
Schmitz M, Graf C, Gut T, Sirena D, Peter I, Dummer R et al. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses. Gene Ther 2006; 13: 893–905.
Acknowledgements
We thank Bruce Acres and Arend Winter for critically reading the manuscript. The technical assistance by Isabelle Choux-Renardet, Nicolas Futin, Murielle Klein, Catherine Ledoux and Yasmine Schlesinger is highly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rittner, K., Schreiber, V., Erbs, P. et al. Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies. Cancer Gene Ther 14, 509–518 (2007). https://doi.org/10.1038/sj.cgt.7701036
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7701036
Keywords
This article is cited by
-
iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy
Gene Therapy (2014)
-
Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD
Gene Therapy (2012)